Log In
BCIQ
Print this Print this
 

OncoHist

  Manage Alerts
Collapse Summary General Information
Company Xenetic Biosciences Inc.
DescriptionRecombinant human histone H1
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$9.3M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/17/2012

$9.3M

0

0

Get a free BioCentury trial today